Concordance between Plasma and Filter Paper Sampling Techniques for the Lymphatic Filariasis Bm14 Antibody ELISA
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Preparation of Plasma and Blood Filter Paper Samples
2.3. Preparation of Eluates from DBS
2.4. Bm14 Filariasis Cellabs Enzyme Linked Immunosorbent Assay
2.5. Bm14 Filariasis CDC’s Enzyme Linked Immunosorbent Assay
2.6. Statistical Analysis
3. Results
3.1. Categorical Analysis and Comparisons of Plasma and DBS Using Cellabs and CDC ELISA Assays
3.2. Comparing the Plasma and DBS for CELISA and CDC ELISA Samples
3.3. Comparing Difference in Bm14 Antibody Units between Cellabs and CDC Assays
3.4. Correlation Coefficient Analysis of Bm14 Antibody Concentrations from Plasma and Eluates from Filter Paper
4. Discussion
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Simonsen, P.E.; Pedersen, E.M.; Rwegoshora, R.T.; Malecela, M.N.; Derua, Y.A.; Magesa, S.M. Lymphatic filariasis control in Tanzania: Effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission. PLoS Negl. Trop. Dis. 2010, 4, e696. [Google Scholar] [CrossRef] [PubMed]
- Hamlin, K.L.; Moss, D.M.; Priest, J.W.; Roberts, J.; Kubofcik, J.; Gass, K.; Streit, T.G.; Nutman, T.B.; Eberhard, M.L.; Lammie, P.J. Longitudinal monitoring of the development of antifilarial antibodies and acquisition of Wuchereria bancrofti in a highly endemic area of Haiti. PLoS Negl. Trop. Dis. 2012, 6, e1941. [Google Scholar] [CrossRef] [PubMed]
- Shawa, S.T.; Mwase, E.T.; Pedersen, E.M.; Simonsen, P.E. Lymphatic filariasis in Luangwa District, South-East Zambia. Parasit. Vectors 2013, 6, 299. [Google Scholar] [CrossRef] [PubMed]
- Mwakitalu, M.E.; Malecela, M.N.; Pedersen, E.M.; Mosha, F.W.; Simonsen, P.E. Urban lymphatic filariasis in the metropolis of Dar es Salaam, Tanzania. Parasit. Vectors 2013, 6, 286. [Google Scholar] [CrossRef] [PubMed]
- Lau, C.L.; Won, K.Y.; Becker, L.; SoaresMagalhaes, R.J.; Fuimaono, S.; Melrose, W.; Lammie, P.J.; Graves, P.M. Seroprevalence and spatial epidemiology of lymphatic filariasis in American Samoa after successful mass drug administration. PLoS Negl. Trop. Dis. 2014, 8, e3297. [Google Scholar] [CrossRef] [PubMed]
- Weil, G.J.; Kastens, W.; Susapu, M.; Laney, S.J.; Williams, S.A.; King, C.L.; Kazura, J.W.; Bockarie, M.J. The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl. Trop. Dis. 2008, 2, e344. [Google Scholar] [CrossRef] [PubMed]
- Harrington, H.; Asugeni, J.; Jimuru, C.; Gwalaa, J.; Ribeyro, E.; Bradbury, R.; Joseph, H.; Melrose, W.; MacLaren, D.; Speare, R. A practical strategy for responding to a case of Lymphatic filariasis post-elimination in Pacific Islands. Parasit. Vectors 2013, 6, 218. [Google Scholar] [CrossRef] [PubMed]
- Joseph, H.M.; Melrose, W. Applicability of the filter paper technique for detection of antifilarial IgG4 antibodies using the Bm14 filariasis CELISA. J.Parasitol. Res. 2010, 2010, 594687. [Google Scholar] [CrossRef] [PubMed]
- Gass, K.; Beau de Rochars, M.V.; Boakye, D.; Bradley, M.; Fischer, P.U.; Gyapong, J.; Itoh, M.; Ituaso-Conway, N.; Joseph, H.; Kyelem, D.; et al. A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis. PLoS Negl. Trop. Dis. 2012, 6, e1479. [Google Scholar] [CrossRef] [PubMed]
- Weil, G.J.; Curtis, K.C.; Fischer, P.U.; Won, K.Y.; Lammie, P.J.; Joseph, H.; Melrose, W.D.; Brattig, N.W. A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14. Acta Trop. 2011, 120 (Suppl. 1), S19–S22. [Google Scholar] [CrossRef] [PubMed]
- Fenwick, A. The global burden of neglected tropical diseases. Public Health 2012, 26, 233–236. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Global programme to eliminate lymphatic filariasis: Progress report, 2014. Wkly. Epidemiol. Rec. 2015, 90, 489–504. [Google Scholar]
- Cellabs Pty Ltd. Lymphatic Filariasis Bm14 Antibody CELISA; Cellabs Pty Ltd.: Brookvale, Queensland, Australia, 2012. [Google Scholar]
- Centers for Disease Control. Lymphatic Filariasis Bm14CDC HRP TMB-ELISA (Modified by JCU); The Centers for Disease Control: Atlanta, GA, USA, 2012. [Google Scholar]
Standard | N Positive | % Positive (95% Confidence Interval (CI)) | Comparative Test | N Positive | % Positive (95% CI) | McNemar Chi sq | P Value |
---|---|---|---|---|---|---|---|
CELISA Plasma 1:100 | 43 | 47 (37–57) | CELISA Dried blood spot (DBS) 1:100 | 41 | 45 (35–55) | 0.5 | 0.7 |
- | - | - | CDC Plasma 1:50 | 46 | 50 (40–60) | 1.3 | 0.5 |
- | - | - | CDC DBS 1:50 | 44 | 48 (38–58) | 0.2 | 0.9 |
Standard | N Positive | % Positive (95% CI) | Comparative Test | N Positive | % Positive (95% CI) | McNemar Chi sq | P Value |
---|---|---|---|---|---|---|---|
CDC Plasma 1:50 | 46 | 50 (40–60) | CDC DBS 1:50 | 44 | 48 (38–58) | 1.0 | 0.6 |
Standard | Comparative Test | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Odds Ratio (95% CI) | P Value |
---|---|---|---|---|---|---|---|
CELISA Plasma 1:100 | CELISA DBS 1:100 | 88.4% (74.9–96.1) | 93.9% (83.1–98.7) | 92.7% (80.8–95.5) | 90.2% (80.1–95.5) | 116.5 (26.15–519.4) | <0.0001 |
- | CDC Plasma 1:50 | 95.4% (84.2–99.4) | 89.8% (77.8–96.6) | 89.1% (78.1–95.0 | 95.7% (85.0–98.8) | 180.4 (33.2–981.7) | <0.0001 |
- | CDC DBS 1:50 | 95.4% (84.2–99.4) | 93.9% (83.1–98.7) | 93.2% (82.0–97.6) | 95.8% (85.6–98.9) | 314.3 (50.0–1975.4) | <0.0001 |
Standard | Comparative Test | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Odds Ratio (95% CI) | P Value |
---|---|---|---|---|---|---|---|
CDC Plasma 1:50 | CDC DBS1:50 | 97.7% (88.0–99.9) | 93.8% (82.8–98.7) | 93.5% (82.7–97.7) | 97.8% (86.6–99.7) | 645.0 (64.6–6442.6) | <0.0001 |
Group 1 | Group 2 | t-Test | |||||||
---|---|---|---|---|---|---|---|---|---|
Test | Mean log (Antibody unit +1) | Geometric mean | Test | Mean log (Antibody unit +1) | Geometric mean | N | Mean Difference | SD | p |
CELISA Plasma | 1.66 | 45.00 | CELISA DBS | 2.10 | 124.42 | 92 | 0.44 | 0.63 | <0.0001 |
CDC Plasma | 2.03 | 105.62 | CDC DBS | 2.07 | 115.51 | 92 | 0.04 | 0.39 | 0.34 |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Masson, J.; Douglass, J.; Roineau, M.; Aye, K.S.; Htwe, K.M.; Warner, J.; Graves, P.M. Concordance between Plasma and Filter Paper Sampling Techniques for the Lymphatic Filariasis Bm14 Antibody ELISA. Trop. Med. Infect. Dis. 2017, 2, 6. https://doi.org/10.3390/tropicalmed2020006
Masson J, Douglass J, Roineau M, Aye KS, Htwe KM, Warner J, Graves PM. Concordance between Plasma and Filter Paper Sampling Techniques for the Lymphatic Filariasis Bm14 Antibody ELISA. Tropical Medicine and Infectious Disease. 2017; 2(2):6. https://doi.org/10.3390/tropicalmed2020006
Chicago/Turabian StyleMasson, Jesse, Jan Douglass, Maureen Roineau, Khin Saw Aye, Kyi May Htwe, Jeffrey Warner, and Patricia M. Graves. 2017. "Concordance between Plasma and Filter Paper Sampling Techniques for the Lymphatic Filariasis Bm14 Antibody ELISA" Tropical Medicine and Infectious Disease 2, no. 2: 6. https://doi.org/10.3390/tropicalmed2020006
APA StyleMasson, J., Douglass, J., Roineau, M., Aye, K. S., Htwe, K. M., Warner, J., & Graves, P. M. (2017). Concordance between Plasma and Filter Paper Sampling Techniques for the Lymphatic Filariasis Bm14 Antibody ELISA. Tropical Medicine and Infectious Disease, 2(2), 6. https://doi.org/10.3390/tropicalmed2020006